137 related articles for article (PubMed ID: 31050567)
1. Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
Zhang X; Guo X
Leuk Lymphoma; 2019 Nov; 60(11):2844-2846. PubMed ID: 31050567
[No Abstract] [Full Text] [Related]
2. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
3. Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature.
Sun Y; Wang C; Sun Y; Wang J; Rong C; Wu A; Ouyang G; Sheng L
Medicine (Baltimore); 2021 Feb; 100(5):e24385. PubMed ID: 33592885
[TBL] [Abstract][Full Text] [Related]
4. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C; Dumas PY; Bérard E; Bidet A; Delabesse E; Tavitian S; Leguay T; Huguet F; Borel C; Forcade E; Vergez F; Vial JP; Rieu JB; Lechevalier N; Luquet I; Canali A; Klein E; Sarry A; de Grande AC; Pigneux A; Récher C; Largeaud L; Bertoli S
Blood Cancer J; 2024 May; 14(1):91. PubMed ID: 38821940
[TBL] [Abstract][Full Text] [Related]
5. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
[TBL] [Abstract][Full Text] [Related]
6. p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16).
Dai HP; Xue YQ; Wu LL; Pan JL; Gong YL; Wu YF; Zhang J; Wu DP; Chen SN
Int J Hematol; 2012 Dec; 96(6):814-7. PubMed ID: 23054652
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome.
Inaba T; Nishimura H; Saito J; Yamane Y; Nakatani T; Yamamoto M; Uchiyama H; Fujita N
Int J Hematol; 2008 Dec; 88(5):602-605. PubMed ID: 19034612
[No Abstract] [Full Text] [Related]
8. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
9. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
11. Clonal Evolution of Acute Myeloid Leukemia with
Li Y; Su L
Turk J Haematol; 2019 May; 36(2):128-130. PubMed ID: 30201598
[No Abstract] [Full Text] [Related]
12. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
13. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
[No Abstract] [Full Text] [Related]
14. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
[No Abstract] [Full Text] [Related]
16. Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Estey E; Pierce S; Kantarjian H; O'Brien S; Beran M; Andreeff M; Escudier S; Koller C; Kornblau S; Robertson L
Leuk Lymphoma; 1993; 11 Suppl 2():59-63. PubMed ID: 7510196
[No Abstract] [Full Text] [Related]
17. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
18. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
19. Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
Rashidi A; Roullet MR
Br J Haematol; 2012 Sep; 158(5):561. PubMed ID: 22758220
[No Abstract] [Full Text] [Related]
20. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]